4.8 Article

Chondrocyte-specific genomic editing enabled by hybrid exosomes for osteoarthritis treatment

期刊

THERANOSTICS
卷 12, 期 11, 页码 4866-4878

出版社

IVYSPRING INT PUBL
DOI: 10.7150/thno.69368

关键词

Therapeutic genome editing; hybrid exosome; CRISPR; Cas9; osteoarthritis; cartilage; MMP-13

资金

  1. National Key R&D Program of China [2018YFA0903204]
  2. University Grants Committee of Hong Kong [14307218, 14304320, N_CUHK422/18, AoE/M-09/12]
  3. RIF grant [R5013-19]
  4. CUHK-University of Manchester Joint Grant [RAC-2019/20]
  5. National Natural Science Foundation of China [81972116, 81972085, 81772394, 31900046]
  6. Guangdong International Cooperation Project [2021A0505030011]
  7. Guangdong Basic and Applied Basic Research Foundation [2020A1515011581, 2021A1515010985]
  8. Shenzhen Science and Technology Projects [JCYJ20200109150700942, JCYJ20180306170922163, SGDX20201103095800003, GJHZ20200731095606019]
  9. China Postdoctoral Science Foundation [2020M682907, 2021M702286]
  10. Special Funds for the Construction of High-Level Hospitals in Guangdong Province

向作者/读者索取更多资源

This study developed a specific delivery vehicle for gene editing in chondrocytes to attenuate cartilage damage. The results showed that the hybrid delivery vehicle successfully delivered the gene plasmids and suppressed the expression of specific genes in chondrocytes, leading to a decrease in cartilage degradation. This research contributes to alleviating the symptoms and damage of osteoarthritis.
Rationale: A cell-specific delivery vehicle is required to achieve gene editing of the disease-associated cells, so the hereditable genome editing reactions are confined within these cells without affecting healthy cells. A hybrid exosome-based nano-sized delivery vehicle derived by fusion of engineered exosomes and liposomes will be able to encapsulate and deliver CRISPR/Cas9 plasmids selectively to chondrocytes embedded in articular cartilage and attenuate the condition of cartilage damage. Methods: Chondrocyte-targeting exosomes (CAP-Exo) were constructed by genetically fusing a chondrocyte affinity peptide (CAP) at the N-terminus of the exosomal surface protein Lamp2b. Membrane fusion of the CAP-Exo with liposomes formed hybrid CAP-exosomes (hybrid CAP-Exo) which were used to encapsulate CRISPR/Cas9 plasmids. By intra-articular (IA) administration, hybrid CAP-Exo/Cas9 sgMMP-13 entered the chondrocytes of rats with cartilage damages that mimicked the condition of osteoarthritis. Results: The hybrid CAP-Exo entered the deep region of the cartilage matrix in arthritic rats on IA administration, delivered the plasmid Cas9 sgMMP-13 to chondrocytes, knocked down the matrix metalloproteinase 13 (MMP-13), efficiently ablated the expression of MMP-13 in chondrocytes, and attenuated the hydrolytic degradation of the extracellular matrix proteins in the cartilage. Conclusion: Chondrocyte-specific knockdown of MMP-13 mitigates or prevents cartilage degradation in arthritic rats, showing that hybrid CAP-Exo/Cas9 sgMMP-13 may alleviate osteoarthritis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据